Holders over time
- ACCV
- TMO
| Quarter | ACCV | TMO |
|---|---|---|
| Q4 2020 | none listed holders, n.a. | 33 holders, $39.2bn |
| Q1 2021 | none listed holders, n.a. | 35 holders, $36.5bn |
| Q2 2021 | none listed holders, n.a. | 33 holders, $38.3bn |
| Q3 2021 | none listed holders, n.a. | 32 holders, $42.6bn |
| Q4 2021 | none listed holders, n.a. | 38 holders, $50.1bn |
| Q1 2022 | none listed holders, n.a. | 32 holders, $43.2bn |
| Q2 2022 | none listed holders, n.a. | 33 holders, $38.9bn |
| Q3 2022 | none listed holders, n.a. | 26 holders, $34.3bn |
| Q4 2022 | none listed holders, n.a. | 29 holders, $37.0bn |
| Q1 2023 | none listed holders, n.a. | 35 holders, $37.1bn |
| Q2 2023 | none listed holders, n.a. | 39 holders, $33.5bn |
| Q3 2023 | none listed holders, n.a. | 39 holders, $32.6bn |
| Q4 2023 | none listed holders, n.a. | 41 holders, $32.7bn |
| Q1 2024 | none listed holders, n.a. | 30 holders, $34.1bn |
| Q2 2024 | none listed holders, n.a. | 38 holders, $30.6bn |
| Q3 2024 | none listed holders, n.a. | 30 holders, $33.8bn |
| Q4 2024 | none listed holders, n.a. | 36 holders, $27.6bn |
| Q1 2025 | none listed holders, n.a. | 31 holders, $24.2bn |
| Q2 2025 | none listed holders, n.a. | 39 holders, $18.8bn |
| Q3 2025 | none listed holders, n.a. | 32 holders, $21.9bn |
| Q4 2025 | none listed holders, n.a. | 32 holders, $29.9bn |
| Q1 2026 | none listed holders, n.a. | 34 holders, $24.4bn |
| Q2 2026 | none listed holders, n.a. | 36 holders, $26.4bn |
| Q3 2026 | 7 holders, $38m | 35 holders, $40.3bn |
- Holders
- 7
- Reported value
- $38m
- Buyers
- 23
- Sellers
- 0
Not ranked this quarter: its new positions are allocations in a new listing.
Thermo Fisher Scientific Inc
- Holders
- 35
- Reported value
- $40.3bn
- Buyers
- 20
- Sellers
- 30
Breadth -10 among 89 comparable managers.
Who holds both, Q3 2026
Both (0)
No tracked manager lists every one of them.
Only ACCV (7)
Davidson Kempner Capital Management LP, Discovery Capital Management LLC, Element Capital Management LLC, Hudson Bay Capital Management LP, Moore Capital Management LP, Soros Fund Management LLC, Steadfast Capital Management LP
Only TMO (35)
AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., D1 Capital Partners LP, Dodge & Cox, Egerton Capital UK LLP, Farallon Capital Management LLC, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Glenview Capital Management LLC, Holocene Advisors LP, Invesco Ltd, Lone Pine Capital LLC, Man Group PLC, Markel Group Inc, Maverick Capital Ltd, and 10 more
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.